Mr. Gu practiced law with Covington & Burling LLP in Shanghai, Washington, D.C., and New York for approximately 8 years before joining Han Kun Law Offices in 2022. Prior to Covington, Mr. Gu also interned and worked for many years in the New York office of Jun He Law Offices and the Shanghai office of Advokatfirman Vinge KB.
Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical, and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, and drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities.
Specifically, Mr. Gu covers a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review" and the Chambers Life Sciences Global Practice Guide (2022).

Bar Admissions
PRC Bar Qualification
Member of the New York State Bar

Education
Mr. Gu received a Bachelor of Laws and a Bachelor of Economics from East China University of Political Science and Law and Shanghai University of International Business and Economics, respectively. He also received an LL.M. degree from NYU School of Law.

• China's HGR Draft Rules Signal Regulatory Easing: Key Takeaways from the Implementing Rules for the Administrative Regulation on Human Genetic Resources (Draft for Comments)

  By Yang (Aaron) Gu, Cathy ZHENG, Matt ZHANG, Franky YU, Naifang ZHANG, Shuwen SUN, Xiaofu NING, Xiaohe ZHAO, Lingyu SHENG, Jingjing XU |May 2026

• China New Biomedical Technology Regulations (Order No. 818) Enter into Force - Dual-Track System for Product Registration / Clinical Translation and Application Finally Takes Effect

  By Yang (Aaron) Gu, Cathy ZHENG, Matt ZHANG, Franky YU, Naifang ZHANG, Shuwen SUN, Xiaofu NING, Xiaohe ZHAO, Lingyu SHENG, Jingjing XU |May 2026

• Key Takeaways from the Implementation Regulations of the Drug Administration Law (2026)

  By Yang (Aaron) Gu, Cathy ZHENG, Matt ZHANG, Franky YU, Naifang ZHANG, Shuwen SUN, Krystal ZHAO, Lingyu SHENG |January 2026